Wenzel Spine, Inc., has completed its first procedures and initiated a limited commercial launch in the U.S. of its new panaSIa™ Expandable SI Fusion System.
This system is the first expandable sacroiliac (SI) fusion implant cleared by the FDA, representing a significant advancement in treating sacroiliac joint dysfunction with improved stability and efficiency.
The panaSIa implant is intended for minimally invasive posterior placement and achieves joint stabilization by expanding in a controlled manner across the ilium and sacrum.
This offers immediate mechanical stability while preserving surrounding tissue. Its integrated graft chamber allows for bone grafting after expansion without removing the instruments, supporting optimal conditions for fusion and reducing procedural complexity.
The panaSIa SI Fusion System is a posteriorly placed, expandable implant that connects the ilium and sacrum to stabilise the SI joint and support fusion.
It comes in two sizes to suit different anatomies, while its simple instrumentation allows for straightforward minimally invasive placement. The implant’s expansion feature, along with its graft delivery system after expansion, simplifies the procedure and may shorten operating time.
The initial U.S. procedures are part of a limited commercial release at selected surgical centres ahead of a full launch planned for the fourth quarter of 2025.
The panaSIa system is intended to expand Wenzel Spine’s range of stand-alone expandable fusion technologies and highlights the company’s ongoing focus on minimally invasive innovation and clinician-focused design.
